- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05860959
SUBLOCADO Resultados a largo plazo
Un estudio longitudinal de fase IV de resultados clínicos de SUBLOCADE (SUBUTEX de liberación prolongada) en adultos con trastorno por consumo de opiáceos (dependencia de opiáceos)
This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Long-term patterns of abstinence/opioid misuse as well as measures of participants' physical, psychological, social, and economic well-being will be monitored to better understand factors associated with recovery from opioid use disorder (OUD). Therefore, this study will observe participants up to a maximum of 4 years.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
This is a Phase IV, prospective, multicentre, multinational, open-label, real-world observational study in participants with current or a history of OUD/opioid dependence.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Richmond, Australia, VIC 3121
- Turning Point
-
-
Melbourne
-
Fitzroy, Melbourne, Australia, 3065
- St Vincent's Hospital Melbourne
-
-
New South Wales
-
Newcastle, New South Wales, Australia, 2300
- John Hunter Hospital
-
-
South Australia
-
Stepney, South Australia, Australia, 5069
- Drug and Alcohol Services South Australia (DASSA)
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2E2R2
- Smart Clinic
-
Edmonton, Alberta, Canadá, T5J 3E4
- Recovery Alberta
-
-
British Columbia
-
Surrey, British Columbia, Canadá, V3T 0H1
- Fraser Health Authority
-
-
Ontario
-
Burlington, Ontario, Canadá, L7M 4X9
- Dr. J.S. Dhillon Medicine Prof. Corp
-
Hamilton, Ontario, Canadá, L8N 1H3
- The Stipley Clinic
-
Owen Sound, Ontario, Canadá, N4K 6M9
- Brightshores Health System
-
Sarnia, Ontario, Canadá, N7T 5W9
- Bluewater Rapid Assessment Addiction Medicine Clinic
-
Toronto, Ontario, Canadá, M4J 1M3
- Comprehensive Treatment Clinic
-
-
-
-
California
-
Costa Mesa, California, Estados Unidos, 92626
- ATP Clinical Research
-
Escondido, California, Estados Unidos, 92025
- Neighborhood Healthcare-Institute of Health
-
-
Connecticut
-
Westport, Connecticut, Estados Unidos, 06880
- Elevate Health and Wellness
-
-
Florida
-
Hialeah, Florida, Estados Unidos, 33012
- United Research Institute
-
Hollywood, Florida, Estados Unidos, 33021
- Zenith Clinical Research LLC
-
Miami, Florida, Estados Unidos, 33126
- Jackson Health Community Center
-
Miami, Florida, Estados Unidos, 33134
- G+C Research Group
-
-
Georgia
-
Decatur, Georgia, Estados Unidos, 30033-4004
- Atlanta VA Medical Center
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- University of Kansas Medical Center
-
Prairie Village, Kansas, Estados Unidos, 66210
- Collective Medical Research.
-
-
Maine
-
Scarborough, Maine, Estados Unidos, 04074-7163
- Maine Health
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21229
- Maryland Treatment Centers
-
-
Massachusetts
-
Springfield, Massachusetts, Estados Unidos, 01199
- Baystate Health
-
-
Michigan
-
Dearborn, Michigan, Estados Unidos, 48124
- THRYV Clinical Studies
-
Dearborn Heights, Michigan, Estados Unidos, 48127
- Vida Clinical Studies
-
Detroit, Michigan, Estados Unidos, 48201
- Wayne State University Hospital
-
Fair Haven, Michigan, Estados Unidos, 48023
- North Point Medical Center
-
Grand Rapids, Michigan, Estados Unidos, 49503-4224
- SHMG Center for Integrative Medicine
-
-
Mississippi
-
Tupelo, Mississippi, Estados Unidos, 38801
- North Mississippi Medical Center
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63141-8704
- Psych Care Consultants
-
-
New York
-
Amherst, New York, Estados Unidos, 14226
- DENT Neurologic Institute
-
Binghamton, New York, Estados Unidos, 13903
- United Health Services
-
New York, New York, Estados Unidos, 10029
- Icahn School of Medicine at Mount Sinai
-
North New Hyde Park, New York, Estados Unidos, 11042
- Core Clinical Trials
-
Rockville Centre, New York, Estados Unidos, 11570
- Stuart Wasser Practice
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28277
- Onsite Clinical Solutions LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73112
- Pahl Pharmaceutical Professionals LLC
-
-
Oregon
-
Corvallis, Oregon, Estados Unidos, 97330
- Healing Comfort Clinic, LLC
-
-
Pennsylvania
-
Narberth, Pennsylvania, Estados Unidos, 19072
- Thalia Medical Centre
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29407
- Charleston Pain and Rehabilitation Center
-
Columbia, South Carolina, Estados Unidos, 29205
- Midlands Neurology
-
Greenville, South Carolina, Estados Unidos, 29605
- Prisma Health
-
-
Texas
-
Houston, Texas, Estados Unidos, 77043
- Biopharma Informatic, Inc. Research Center
-
-
Utah
-
Clinton, Utah, Estados Unidos, 84015
- Alpine Research Organization
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23219
- Virginia Commonwealth University
-
-
-
-
-
Linköping, Suecia, 58185
- Linkoping University Hospital, Psychiatry Center
-
Stockholm, Suecia, SE-11365
- Beroendecentrum
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Participants may enroll if they have initiated treatment with SUBLOCADE within 3 months prior to signing the informed consent form (ICF), or have completed an Indivior SUBLOCADE study (eg, INDV-6000-401, INDV-6000-405) and received their last dose of SUBLOCADE on the study within 3 months prior to signing the ICF, and plan to receive additional SUBLOCADE injections.
Descripción
Inclusion Criteria:
Participants must meet all of the following criteria:
-
Is an adult ≥ 18 years of age who has signed the informed consent form
-
Plans to receive additional SUBLOCADE injections and
-
Has initiated treatment for OUD/opioid dependence with SUBLOCADE within the last 3 months prior to Baseline Visit
- OR
-
Has completed an Indivior SUBLOCADE study (eg, INDV-6000-401, INDV-6000-405) and has received the last dose of SUBLOCADE on that study within 3 months prior to Baseline Visit
-
-
Is not currently participating in any clinical trial requiring medical intervention
-
Is not currently using opioids to treat a diagnosis other than OUD/opioid dependence
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Participants achieving DSM-5 remission, early or sustained, (yes/no) while on initial SUBLOCADE treatment by 6 months and 1, 1.5, 2, 2.5, and 3 years from study Baseline
Periodo de tiempo: up to a maximum of 4 years
|
|
up to a maximum of 4 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Key Secondary: Participants with "no symptoms" or improving by ≥1 DSM-5 severity classification within the last 3 months (moderate to mild, or severe to mild or moderate) relative to study Baseline (yes/no) at Month 6 and Years 1, 2, and 3
Periodo de tiempo: up to a maximum of 4 years
|
DSM-5-Related |
up to a maximum of 4 years
|
|
Among those starting SUBLOCADE within 3 months of study Baseline, time to achieve early remission for the first time while on initial SUBLOCADE treatment
Periodo de tiempo: up to a maximum of 4 years
|
DSM-5-Related |
up to a maximum of 4 years
|
|
Participants achieving DSM-5 sustained remission (yes/no) by 1, 1.5, 2, 2.5, and 3 years while on initial SUBLOCADE treatment
Periodo de tiempo: up to a maximum of 4 years
|
DSM-5-Related |
up to a maximum of 4 years
|
|
Time to achieve sustained remission for the first time while on initial SUBLOCADE treatment
Periodo de tiempo: up to a maximum of 4 years
|
DSM-5-Related |
up to a maximum of 4 years
|
|
Time to discontinuing initial SUBLOCADE treatment and the corresponding reasons for discontinuation, eg, resolution of OUD symptoms, safety concerns, treatment failure, or seeking alternative MOUD treatment
Periodo de tiempo: up to a maximum of 4 years
|
MOUD Use and Retention |
up to a maximum of 4 years
|
|
Participants switching from initial SUBLOCADE treatment to another MOUD (yes/no), and the corresponding reasons, eg, safety concerns, treatment failure, seeking alternative MOUD treatment
Periodo de tiempo: up to a maximum of 4 years
|
MOUD Use and Retention |
up to a maximum of 4 years
|
|
The overall treatment duration for participants who stop initial SUBLOCADE treatment as the result of resolution of OUD symptoms
Periodo de tiempo: up to a maximum of 4 years
|
MOUD Use and Retention |
up to a maximum of 4 years
|
|
Participants with any positive opioid use in the past month (yes/no) at Month 6 and Years 1, 2, and 3 while on initial SUBLOCADE treatment
Periodo de tiempo: up to a maximum of 4 years
|
Illicit Opioid Use (Self-Reports) |
up to a maximum of 4 years
|
|
Participants with opioid overdose requiring intervention (yes/no) while on initial SUBLOCADE treatment at least once during the first 6 months, and during Years 1, 2, and 3
Periodo de tiempo: up to a maximum of 4 years
|
Opioid Overdose Requiring Intervention |
up to a maximum of 4 years
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- INDV-6000-406
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .